Profit warning batters Bayer in stock market

27 July 2017

Reduced growth forecasts at German life sciences group Bayer (BAYN: DE) hit the company’s stocks hard on Thursday morning, with its share price sliding by 3% to 108.65 euros in the fours hours after the announcement of the latest quarterly financials.

Bayer’s pharma unit is performing well but declines in crop science have hit the group’s overall outlook for the year, with the company now expecting its sales to be more than 49 billion euros ($57.4 billion), having previously predicted 51 billion euros.

The company’s preferred profit measure, adjusted earnings before interest tax, depreciation and amortization (EBITDA), will increase by a high-single digit percentage, Bayer now predicts, compared to earlier estimates of growth in the low teens.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK